Received Oct 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA MNEXSPIKE)) | MODERNA | UNK | — | IM |
a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more; a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more; all the symptoms of COVID after receiving mNEXSPIKE; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more), ANOSMIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more) and COVID-19 (all the symptoms of COVID after receiving mNEXSPIKE) in a female patient of an unknown age who received mRNA-1283 (MNEXSPIKE PFS) for COVID-19 prophylaxis. Co-suspect product included Pre-filled Syringe injection for COVID-19 prophylaxis. No Medical History information was reported. On 09-Oct-2025, the patient received dose of mRNA-1283 (MNEXSPIKE PFS) (Intramuscular use) .2 milliliter. On an unknown date, the patient started Pre-filled Syringe (unknown route) at an unspecified dose. In October 2025, the patient experienced AGEUSIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more), ANOSMIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more) and COVID-19 (all the symptoms of COVID after receiving mNEXSPIKE). In October 2025, AGEUSIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more), ANOSMIA (a severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. SM lost that for three days and maybe a little more) and COVID-19 (all the symptoms of COVID after receiving mNEXSPIKE) had resolved. Concomitant medications were not reported. It was reported that patient had severe reaction including all the symptoms of COVID after receiving mNEXSPIKE last week, including the taste and smell. Patient lost that for three days and maybe a little more and wanted to know if it was something that had been reported at all. Patient did report her side effects to the pharmacist, though she hadn't had the food and smell yet at that time. The pharmacist wasn't saying that it was COVID itself and wanted to know if the side effects patient had experienced made it real COVID or some kind of reaction to vaccine. Reporter wanted to know if patient could be contagious if she was coughing and sneezing around other people, if she could give them COVID-19. Treatment information was not reported.; Reporter's Comments: The benefit -risk relationship of product is not affected by this report.